• Publications
  • Influence
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
TLDR
Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival, and overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating thatSLND alone is noninherited.
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011
TLDR
Despite the potential for residual axillary disease after SLND, SLND without ALND can offer excellent regional control and may be reasonable management for selected patients with early-stage breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.
Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
TLDR
A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth
TLDR
Adding trastuzumab to chemotherapy, as used in this trial, significantly increased pathologic complete response (pCR) rate without clinical congestive heart failure, according to the small sample size.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
TLDR
Among women with cN1 breast cancer receiving neoadjuvant chemotherapy who had 2 or more SLNs examined, the FNR was not found to be 10% or less, and changes in approach and patient selection that result in greater sensitivity would be necessary to support the use of SLN surgery as an alternative to ALND.
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
TLDR
Marking nodes with biopsy-confirmed metastatic disease allows for selective removal and improves pathologic evaluation for residual nodal disease after chemotherapy, as determined in patients undergoing complete axillary lymphadenectomy.
Primary treatment of cystosarcoma phyllodes of the breast
TLDR
The rate of local and distant failure, as well as potential prognostic factors, are evaluated, to better define appropriate treatment strategies for cystosarcoma phyllodes.
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized
TLDR
Findings do not support routine use of axillary lymph node dissection in this patient population based on 10-year outcomes, and overall survival for patients treated with sentinel lymph nodes dissection alone was noninferior toOverall survival for those treated with axillary node dissections.
Invasive neuroendocrine carcinoma of the breast
TLDR
The purpose of this first case‐controlled study is to reveal the clinicopathologic features, therapeutic response, and outcomes of patients with NEC of the breast.
...
1
2
3
4
5
...